Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Molecular Analysis for Therapy Choice (MATCH)

Next Previous
Trial Profile

Molecular Analysis for Therapy Choice (MATCH)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABSK 091 (Primary) ; Adavosertib (Primary) ; Afatinib (Primary) ; Binimetinib (Primary) ; Capivasertib (Primary) ; Copanlisib (Primary) ; Crizotinib (Primary) ; Dabrafenib (Primary) ; Dasatinib (Primary) ; Defactinib (Primary) ; Erdafitinib (Primary) ; GSK 2636771 (Primary) ; Ipatasertib (Primary) ; Larotrectinib (Primary) ; Nivolumab (Primary) ; Osimertinib (Primary) ; Palbociclib (Primary) ; Pertuzumab (Primary) ; Sapanisertib (Primary) ; Sunitinib (Primary) ; Taselisib (Primary) ; Trametinib (Primary) ; Trastuzumab emtansine (Primary) ; Ulixertinib (Primary) ; Vismodegib (Primary)
  • Indications Adenocarcinoma; Adenoid cystic carcinoma; Advanced breast cancer; Anal cancer; Bladder cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; CNS cancer; Colorectal cancer; Endometrial cancer; Gastrointestinal cancer; Glioblastoma; Gliosarcoma; Haemangiosarcoma; Head and neck cancer; Leiomyosarcoma; Liver cancer; Lung cancer; Lymphoma; Malignant melanoma; Mesothelioma; Multiple myeloma; Non-small cell lung cancer; Oesophageal cancer; Osteosarcoma; Ovarian cancer; Pancreatic cancer; Perivascular epithelioid cell tumours; Prostate cancer; Renal cell carcinoma; Salivary gland cancer; Sarcoma; Solid tumours; Squamous cell cancer; Thyroid cancer; Triple negative breast cancer; Urogenital cancer; Uterine cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms MATCH; NCI-MATCH; NCI-MATCH ECOG-ACRIN Trial (EAY131)

    • Most Recent Events

    • 06 Jun 2023 Results of an analysis assessing molecular profiling of ctDNA from patients enrolled in this trial for treatment with mTOR1/2 inhibitor sapanisertib (arm M) and the Hedgehog pathway inhibitor vismodegib (arm T) presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2023 Results of subprotocols C1 (n=44) and C2 (n=20) assessing efficacy of crizotinib in patients with MET amplification and MET exon 14 deletion, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2023 Results of Discovery of gene fusions in driver-negative NCI-MATCH screening samples, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top